Latest news with #KellyHuang
Business Wire
2 days ago
- Health
- Business Wire
Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. Cardiovascular disease continues to be a critical public health issue in the United States, remaining the leading cause of death nationwide. In 2022, heart disease claimed over 700,000 lives—nearly 1 in every 5 deaths—underscoring the urgent need for early detection and intervention. 1 Despite advances, many high‑risk patients remain undiagnosed until they experience serious cardiac events. The proposed rule by CMS marks a significant step toward broader access to innovative, evidence-based imaging tools that help identify high-risk cardiovascular patients earlier and more accurately. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. 'We commend CMS for ensuring that the proposed payment level reflects the clinical value, technological investment, and expertise needed to perform this service, enabling Medicare beneficiaries to access this technology.' Coronary computed tomography angiography (CTA) with plaque analysis offers invaluable insights into plaque burden, composition, and morphology, enabling earlier and more accurate identification of high-risk patients who may benefit from targeted medical therapy and lifestyle interventions. Numerous studies have demonstrated that such non-invasive imaging enhances risk stratification and clinical decision-making while reducing the need for more invasive and costly diagnostic procedures. 'Elucid remains optimistic as we await the final publication of the code and payment, effective January 1, 2026,' said Huang. 'We recognize the efforts of societies and physician organizations collaborating with the AMA and CMS to reach an appropriate payment level. We look forward to continued cooperation to enhance patient outcomes and access.' The proposed rule outlines payment policies and rates for services furnished under Medicare Part B. The inclusion of coronary CTA with plaque analysis represents a significant advancement for precision cardiovascular care. It follows a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357. This has already allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
National Post
10-07-2025
- Health
- National Post
Elucid to Showcase PlaqueIQ™ at SCCT 2025
Article content BOSTON — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ™ image analysis software at the 20 th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal. Article content Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly's presentation, 'Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,' will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization. Article content Elucid will also host a breakfast symposium, ' From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,' Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid's software and share how these findings influence treatment pathways. The program will also explore FFR CT features on an investigational basis. 1 'The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,' said Dr. Berlacher. 'Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.' Article content In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, 'CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,' features Dr. Ahmadi, and will also include product demos. Article content Attendees may also participate in hands-on demos of Elucid's flagship PlaqueIQ image analysis software, as well as its FFR CT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid's senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET. Article content PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content
Yahoo
10-07-2025
- Business
- Yahoo
Elucid to Showcase PlaqueIQ™ at SCCT 2025
Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON, July 10, 2025--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ™ image analysis software at the 20th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal. Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly's presentation, "Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture," will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization. Elucid will also host a breakfast symposium, "From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology," Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid's software and share how these findings influence treatment pathways. The program will also explore FFRCT features on an investigational basis.1 "The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level," said Dr. Berlacher. "Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events." In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, "CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine," features Dr. Ahmadi, and will also include product demos. Attendees may also participate in hands-on demos of Elucid's flagship PlaqueIQ image analysis software, as well as its FFRCT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid's senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFRCT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit ____________________ 1 Elucid is pursuing an indication for FFRCT, derived from its plaque algorithm. This software is currently investigational and not cleared for use by the FDA. View source version on Contacts Media Contact: Sam ChoinskiPazanga Health Communications(860) 301-5058schoinski@
Business Wire
10-07-2025
- Business
- Business Wire
Elucid to Showcase PlaqueIQ™ at SCCT 2025
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ™ image analysis software at the 20 th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. The software is designed to help physicians prioritize and personalize treatment based on actual disease. Share Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly's presentation, 'Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,' will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization. Elucid will also host a breakfast symposium, ' From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,' Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid's software and share how these findings influence treatment pathways. The program will also explore FFR CT features on an investigational basis. 1 'The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,' said Dr. Berlacher. 'Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.' In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, 'CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,' features Dr. Ahmadi, and will also include product demos. Attendees may also participate in hands-on demos of Elucid's flagship PlaqueIQ image analysis software, as well as its FFR CT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid's senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Forbes
24-03-2025
- Business
- Forbes
How To Celebrate Women's History Month: 14 Creative Ideas For Leaders
National Women's History Month is an opportunity for leaders to go beyond simple recognition and take meaningful action to support the contributions of women in their organizations. But what does that look like in practice? From spotlighting their achievements to investing in their long-term career growth, there are many ways to demonstrate a company's genuine commitment to uplifting women—not just in March but year-round. Below, 14 members of Forbes Coaches Council share some creative and impactful ways to celebrate and support women in the workplace, which in turn can help foster a culture where recognition and opportunity go hand in hand for every team member. Women want what everyone wants—respect, recognition and opportunity. Use National Women's History Month to highlight contributions, past and present. Acknowledge impact with a team gathering for a coffee break or a full-day event. Recognize achievements big and small, reinforcing that every role matters. Most importantly, honor women with equal opportunities, fair pay and a culture of respect. - Barbara Zuleger, Performance Partners Coaching Many DEI celebrations fall into brief acknowledgments without deep, personal engagement. A powerful approach is to host a 'Totality of Me' workshop. This exercise encourages employees to map and share their multifaceted identities—going beyond gender, background and roles. It fosters deeper connections and sees women as whole, unique people rather than as labels. - Dou Dou, Visions Alive Leaders can celebrate Women's History Month by creating a library of recorded interviews highlighting the diverse career paths of influential women in their organization. This builds a permanent, growing resource that centers women's voices rather than making them passive recipients of recognition, provides mentorship opportunities, aids retention and demonstrates commitment beyond March. - Keirsten Greggs, TRAP Recruiter, LLC In addition to highlighting female leadership within the company in March, consider activities and gatherings that celebrate women's contributions throughout the year. In science, there is even a term for erasing women's contribution: the Matilda Effect. Find opportunities to reverse the Matilda Effect by highlighting female leadership and ingenuity whenever possible. - Kelly Huang, Coach Kelly Huang Forbes Coaches Council is an invitation-only community for leading business and career coaches. Do I qualify? Organizations must celebrate Women's History Month this year because it demonstrates what they truly value versus what they value when it is convenient and comfortable. To celebrate, hold an event or create a media campaign where male leaders recognize their greatest female mentors. This will showcase the contributions of women and their impact while demonstrating support from their male colleagues. - Jill Helmer, Jill Helmer Consulting Companies can celebrate women by recognizing their contributions in meaningful ways, starting with fair and equitable pay that reflects their talents and value. Beyond compensation, leaders can amplify women's voices by offering them key opportunities for leadership, mentorship and professional growth. Hosting storytelling sessions where women share their journeys, lessons and successes fosters inspiration and connection. - Veronica Angela, CONQUER EDGE, LLC Create a 'Future Women Leaders Fund,' offering mentorship, executive coaching or professional development grants to high-potential women within the company. Instead of one-off appreciation posts, this initiative creates a lasting impact by directly investing in women's growth and leadership paths. Recognition matters, but opening doors and making opportunities tangible matters more. - Alla Adam, Adam Impact Institute One suggestion is highlighting how women across all levels have contributed to achieving organizational goals and uplifting others. Invite presenters to share specific outcomes, such as improved team performance or mentorship successes, through short talks or visual displays. By spotlighting these efforts, leaders reinforce a culture of recognition and inspire continued growth in March and beyond. - Kerri Sutey, Sutey Coaching & Consulting LLC Company leaders can go beyond symbolic gestures by amplifying women's voices—host a panel of female leaders, spotlight their contributions and commit to real mentorship and sponsorship opportunities. Do more than one of these throughout the month. Actions speak louder than words, and investing in women's growth strengthens innovation, engagement and equity—benefiting the entire organization. - Lynda Silsbee, Alliance for Leadership Acceleration Create a large poster made up of headshots of women from across the organization. Post it during March. To obtain engagement, host a professional headshot day. It doesn't have to be anything fancy or too costly. Take pictures in iconic places within your worksites that make the women the stars in front of amazing backgrounds. This poster will enhance their visibility and confidence and become a keepsake. - Miriam Simon, Mi Sí Coaching and Consulting LLC Speak to women's contributions every day, not just during the month of March. Give your female employees the opportunity to spotlight their contributions, passions and strengths as a means of sponsoring their work—create a stage for them to speak to their impact beyond Women's History Month. - Suzanne Weller, Weller Collaboration Flip the script. Instead of just praising women, hand them the mic. Let women across all levels take over leadership meetings, company town halls or social channels for a day—sharing their insights, challenges and visions for the future. The real celebration isn't about words; it's about giving women the power to be heard, be seen and truly lead. Lengthen this period beyond the month, too! - Arthi Rabikrisson, Prerna Advisory Companies can celebrate women similarly to planning a birthday party for oneself—for a milestone you're truly dreading and knowing nobody is going to show up. If you want to honor and celebrate women, use AI to generate a list of conversation starters and learn how you can take the initiative to help! Be part of a solution and a bystander no more. Protect females from a scary world. These women are also fighting for your little girls. - Kinga Vajda, Execute Your Intentions, LLC To demonstrate commitment to gender diversity and inclusion and create a more welcoming and supportive environment for women, create a 'Women in Leadership' spotlight series. Feature a different woman leader from a different level of the company each week. This provides visibility and recognition for women's contributions while showcasing their achievements and inspiring others. - Donna Grego-Heintz, UpWords
